ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis.

Trial Profile

ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Rosuvastatin (Primary) ; Clopidogrel
  • Indications Coronary artery disease; Embolism and thrombosis; Myocardial reperfusion injury
  • Focus Biomarker; Therapeutic Use
  • Acronyms ROMA
  • Most Recent Events

    • 25 Oct 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Actual initiation date (March 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top